Quarterly report pursuant to Section 13 or 15(d)

Revenue from Contracts with Customers (Tables)

v3.23.3
Revenue from Contracts with Customers (Tables)
9 Months Ended
Jun. 30, 2023
Revenue from Contracts with Customers [Abstract]  
Revenue from Customers by Products

Three Months Ended

Nine Months Ended

June 30,

June 30,

2023

2022

2023

2022

FC2

U.S. prescription channel

$

863,379

$

6,736,158

$

5,172,543

$

29,900,890

Global public health sector

2,478,031

2,866,037

7,249,315

6,864,831

Total FC2

3,341,410

9,602,195

12,421,858

36,765,721

ENTADFI

(225)

13,088

Net revenues

$

3,341,185

$

9,602,195

$

12,434,946

$

36,765,721

Revenue by Geographic Area

Three Months Ended

Nine Months Ended

June 30,

June 30,

2023

2022

2023

2022

United States

$

1,449,883

$

7,024,786

$

7,046,518

$

30,780,271

South Africa

612,000

*

1,941,678

*

Other

1,279,302

2,577,409

3,446,750

5,985,450

Net revenues

$

3,341,185

$

9,602,195

$

12,434,946

$

36,765,721

*Less than 10% of total net revenues